17 June 2019 - While noting some progress in its Brexit preparations on transferring medicine marketing authorizations from the UK to the EU, the European Medicines Agency on Monday announced a series of activities that will ramp up, in addition to the highest priority activities, for the remainder of 2019.

But EMA also reiterated that between 20% and 25% of the agency’s staffers are expected to leave. And in the most recent EMA update, of the agency’s 776 staff members, 464 have relocated to the EMA’s new headquarters in the Netherlands, but 312 are working remotely, mostly from London.

“Due to resource constraints, most activities temporarily suspended at the end of 2018 remain on hold. These include guideline development, most working party meetings, engagement in international activities and the proactive publication of clinical data. A further review by EMA's Management Board will take place in October 2019,” EMA said.

Read Regulatory Affairs Professional Society article